COVID-19 Quick Start - Test and Treat in Africa

NCT06360783 | Completed

• 1 other identifier: Pro00111388
• Study Type: observational
• Target: 148
• Locations: 1 country
• Sites: 1

Brief Summary

Duke University and the Clinton Health Access Initiative (CHAI), in partnership with the Ministries of Health (MoH) of Ghana, Malawi, Rwanda, Zambia, and Zimbabwe, aim to assess the implementation and impact of COVID-19 test -and -treat (T\&T) demonstration programs

Conditions

COVID-19

Outcome Measures

Primary Outcomes (1)

• Stakeholder Perspectives

  Assess perspectives from key stakeholders including MoH and public sector personnel, healthcare workers, and patients on feasibility and acceptability of COVID-19 T\&T programs as implemented

  up to 3 years

Study Arms (5)

Ghana

Aggregated testing and treatment data from centers in Ghana.

Malawi

Aggregated testing and treatment data from centers in Malawi.

Rwanda

Aggregated testing and treatment data from centers in Rwanda.

Zambia

Aggregated testing and treatment data from centers in Zambia.

Zimbabwe

Aggregated testing and treatment data from centers in Zimbabwe.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients in participating countries who receive COVID testing and treatment at a participating facility.

You may qualify if:

• years and older
• Able to provide informed consent
• Patients who have received COVID-19 testing and/or treatment at the facility
• Have a positive COVID-19 test and were prescribed oral antiviral medication (and may or may not have initiated on treatment (Only for subset of patients who will be followed to assess treatment completion and outcomes)

Sponsors & Collaborators

• Duke University: lead
• Duke Clinical Research Institute: collaborator
• Clinton Health Access Initiative, Nigeria: collaborator

Study Sites (1)

Duke Global Health Institute

Durham, North Carolina, 27705, United States

Location

Related Publications (1)

• Narayanasamy S, Gambanga F, Boeke CE, Udayakumar K, Brothers L, Wolfe CR, Agwuocha C, Asamoa-Amoakohene MN, Detleuxay K, Griffith BC, Hamza N, Joseph J, Kimani P, Kirungi R, Lufesi N, Mbewe N, McCarthy E, Mulenga M, Mukiibi M, Mwenifumbo T, Ofori-Boadu L, Okoli IU, Phongphila S, Regan S, Rwagasore E, Staple A, Tebor J, Tomno W, Umuraza S, Bosworth HB; COVID Treatment QuickStart Consortium Members; COVID-19 QuickStart Consortium Members. Mixed methods implementation research of oral antiviral treatment for COVID-19 in low- and middle-income countries: a study protocol. BMJ Open. 2025 Sep 18;15(9):e088465. doi: 10.1136/bmjopen-2024-088465.

  PMID: 40973372 DERIVED

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Krishna Udayakumar, MD

  Duke University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 9, 2024
• First Posted: April 11, 2024
• Study Start: February 1, 2023
• Primary Completion: May 31, 2024
• Study Completion: May 31, 2024
• Last Updated: April 22, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)